Technical Analysis for SNDX - Syndax Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | -5.08% | |
| Wide Bands | Range Expansion | -5.08% | |
| Oversold Stochastic | Weakness | -5.08% | |
| Calm After Storm | Range Contraction | -3.99% | |
| NR7 | Range Contraction | -3.99% | |
| Narrow Range Bar | Range Contraction | -3.99% | |
| Wide Bands | Range Expansion | -3.99% | |
| Oversold Stochastic | Weakness | -3.99% | |
| Stochastic Buy Signal | Bullish | -6.02% | |
| Spinning Top | Other | -6.02% |
| Alert | Time |
|---|---|
| New 52 Week Low | 13 minutes ago |
| Outside Day | 24 minutes ago |
| Down 5% | 24 minutes ago |
| Down 3% | 24 minutes ago |
| Fell Below Previous Day's Low | 24 minutes ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/05/2024
Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company's lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Breast Cancer Antineoplastic Drugs Treatment Of Breast Cancer Lung Cancer Cancer Cell Cancer Therapies Hematological Malignancies Pyridines National Cancer Institute Benzamides Histone Deacetylase Inhibitor
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Breast Cancer Antineoplastic Drugs Treatment Of Breast Cancer Lung Cancer Cancer Cell Cancer Therapies Hematological Malignancies Pyridines National Cancer Institute Benzamides Histone Deacetylase Inhibitor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 25.34 |
| 52 Week Low | 15.03 |
| Average Volume | 1,375,712 |
| 200-Day Moving Average | 20.82 |
| 50-Day Moving Average | 18.71 |
| 20-Day Moving Average | 18.56 |
| 10-Day Moving Average | 17.84 |
| Average True Range | 1.13 |
| RSI (14) | 35.06 |
| ADX | 22.25 |
| +DI | 18.30 |
| -DI | 34.52 |
| Chandelier Exit (Long, 3 ATRs) | 19.10 |
| Chandelier Exit (Short, 3 ATRs) | 18.74 |
| Upper Bollinger Bands | 22.57 |
| Lower Bollinger Band | 14.54 |
| Percent B (%b) | 0.18 |
| BandWidth | 43.28 |
| MACD Line | -0.84 |
| MACD Signal Line | -0.38 |
| MACD Histogram | -0.4613 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.23 | ||||
| Resistance 3 (R3) | 17.16 | 16.68 | 17.01 | ||
| Resistance 2 (R2) | 16.68 | 16.35 | 16.71 | 16.94 | |
| Resistance 1 (R1) | 16.31 | 16.15 | 16.50 | 16.38 | 16.87 |
| Pivot Point | 15.83 | 15.83 | 15.92 | 15.86 | 15.83 |
| Support 1 (S1) | 15.46 | 15.50 | 15.65 | 15.53 | 15.03 |
| Support 2 (S2) | 14.98 | 15.30 | 15.01 | 14.96 | |
| Support 3 (S3) | 14.61 | 14.98 | 14.89 | ||
| Support 4 (S4) | 14.68 |
